Therapeutic options: Addressing the current dilemma

European Neuropsychopharmacology

Volumn 16, Issue SUPPL. 2, 2006, Pages

  Dinan, Timothy ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Generalized anxiety disorder; Pharmacotherapy; Psychotherapy; Treatment algorithms

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; DIAZEPAM; ESCITALOPRAM; IMIPRAMINE; LORAZEPAM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROLACTIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOLOXATONE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANTICHOLINERGIC EFFECT; ARTICLE; ATTENTION DISTURBANCE; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; LONG TERM CARE; MENTAL PATIENT; NAUSEA; ORTHOSTATIC HYPERTENSION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOTHERAPY; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; WEIGHT GAIN;

ADRENERGIC UPTAKE INHIBITORS; AGORAPHOBIA; ALGORITHMS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; BUSPIRONE; HUMANS; PSYCHOTHERAPY; SEROTONIN UPTAKE INHIBITORS;

EID: 33745400924     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.04.004     Document Type: Article

References (64)

1. Aikins D.E., and Craske M.G. Cognitive theories of generalized anxiety disorder. Psychiatr. Clin. North Am. 24 (2001) 57-74
2. Allgulander C., Cloninger C.R., Przybeck T.R., and Brandt L. Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacol. Bull. 34 (1998) 165-166
3. Allgulander C., Dahl A.A., Austin C., Morris P.L., Sogaard J.A., Fayyad R., Kutcher S.P., and Clary C.M. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am. J. Psychiatry 161 (2004) 1642-1649
4. Allgulander C., Hackett D., and Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry 179 (2001) 15-22
5. American Psychiatric Association Task Force on Benzodiazepine Dependency. Risk factors for clinically important physiological benzodiazepine dependence. In: American Psychiatric Association (Ed). Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association (1990) 25-33 Washington, D.C.
6. American Psychiatric Association. Diagnostic criteria for generalized anxiety disorder. In: American Psychiatric Association (Ed). Diagnostic and Statistical Manual of Mental Disorders. Third Edition (1980), Washington, D.C 232-233
7. Borkovec T.D., and Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J. Consult. Clin. Psychol. 61 (1993) 611-619
8. Bourin M., and Malinge M. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Prog. Neuro-psychopharmacol. Biol. Psychiatry 19 (1995) 567-575
9. Brawman-Mintzer, O., Knapp, R., Rynn, M., Carter,R., Rickels, K., 2006. Sertraline treatment for generalized anxiety disorder: results of a double-blind, placebo-controlled study. J. Clin. Psychiatry, in press.
10. Davidson J.R., DuPont R.L., Hedges D., and Haskins J.T. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 60 (1999) 528-535
11. Davidson J.R., Bose A., Korotzer A., and Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety 19 (2004) 234-240
12. de Boer T. The pharmacologic profile of mirtazapine. J. Clin. Psychiatry 57 Suppl. 4 (1996) 19-25
13. DeMartinis N., Rynn M., Rickels K., and Mandos L. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J. Clin. Psychiatry 61 (2000) 91-94
14. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl.) 105 (1991) 428-432
15. Fava M., Mulroy R., Alpert J., Nierenberg A.A., and Rosenbaum J.F. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am. J. Psychiatry 154 (1997) 1760-1762
16. Feighner J.P., and Cohn J.B. Analysis of individual symptoms in generalized anxiety-a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 21 (1989) 124-130
17. Fisher P.L., and Durham R.C. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol. Med. 29 (1999) 1425-1434
18. Gelenberg A.J., Lydiard R.B., Rudolph R.L., Aguiar L., Haskins J.T., and Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283 (2000) 3082-3088
19. Goodnick P.J., Puig A., DeVane C.L., and Freund B.V. Mirtazapine in major depression with comorbid generalized anxiety disorder. J. Clin. Psychiatry 60 (1999) 446-448
20. Hedges D.W., Reimherr F.W., Strong R.E., Halls C.H., and Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol. Bull. 32 (1996) 671-676
21. Hoehn-Saric R., Mcleod D.R., and Zimmerli W.D. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J. Clin. Psychiatry 49 (1988) 293-301
22. Holliday S.M., and Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49 (1995) 280-294
23. Laakmann G., Schule C., Lorkowski G., Baghai T., Kuhn K., and Ehrentraut S. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl.) 136 (1998) 357-366
24. Lader M.H., and Bond A.J. Interaction of pharmacological and psychological treatments of anxiety. Br. J. Psychiatry (1998) 42-48
25. Laverdure B., and Boulenger J.P. Beta-blocking drugs and anxiety. A proven therapeutic value. Encephale 17 (1991) 481-492
26. Livingston M.G., and Livingston H.M. Monoamine oxidase inhibitors. An update on drug interactions. Drug Safety 14 (1996) 219-227
27. Lydiard R.B., Brawman-Mintzer O., and Ballenger J.C. Recent developments in the psychopharmacology of anxiety disorders. J. Consult. Clin. Psychol. 64 (1996) 660-668
28. Mehtonen O.P., Sogaard J., Roponen P., and Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J. Clin. Psychiatry 61 (2000) 95-100
29. Meltzer H.Y., Flemming R., and Robertson A. The effect of buspirone on prolactin and growth hormone secretion in man. Arch. Gen. Psychiatry 40 (1983) 1099-1102
30. National Institute for Clinical Excellence (NICE), 2004. Anxiety. Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. (CG22 Anxiety-Nice guideline). Available from: http://www.nice.org.uk/page.aspx?o=cg022niceguidelines. Accessed May 2006.
31. Nemeroff C.B., and Owens M.J. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr. 9 Suppl. 4 (2004) 23-31
32. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr. Scand. Suppl 391 (1997) 31-37
33. Nutt D.J., and Malizia A.L. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br. J. Psychiatry 179 (2001) 390-396
34. Nutt D., Argyropoulos S., Hood S., and Potokar J. Generalized Anxiety Disorder: A Comorbid Disease. Eur. Neuropsychopharmacol. Suppl. 16 (2006) S105-SII8
35. Pande A.C., Crockatt J.G., Feltner D.E., Janney C.A., Smith W.T., Weisler R., Londborg P.D., Bielski R.J., Zimbroff D.L., Davidson J.R.T., and Liu-Dumaw M. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry 160 (2003) 533-540
36. Pecknold J.C., Matas M., Howarth B.G., Ross C., Swinson R., Vezeau C., and Ungar W. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can. J. Psychiatry 34 (1989) 766-771
37. Pollack M.H., Zaninelli R., Goddard A., McCafferty J.P., Bellew K.M., Burnham D.B., and Iyengar M.K. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry 62 (2001) 350-357
38. Power K.G., Simpson R.J., Swanson V., and Wallace L.A. Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br. J. Gen. Pract. 40 (1990) 289-294
39. Preskorn, S.H., 1999. Outpatient Management of Depression: A Guide for the Primary-Care Practitioner. Evaluating the Various Antidepressants. Available at: http://www.preskorn.com/books/omd_s8.html. Accessed May 2006.
40. Richelson E. Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin. Proc. 69 (1994) 1069-1081
41. Rickels K., and Schweizer E. The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment. Br. J. Psychiatry (1998) 49-54
42. Rickels K., and Rynn M. Pharmacotherapy of generalized anxiety disorder. J. Clin. Psychiatry 63 Suppl. 14 (2002) 9-16
43. Rickels K., Fox I.L., Greenblatt D.J., Sandler K.R., and Schless A. Clorazepate and lorazepam: clinical improvement and rebound anxiety. Am. J. Psychiatry 145 (1988) 312-317
44. Rickels K., Schweizer E., Csanalosi I., Case W.G., and Chung H. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch. Gen. Psychiatry 45 (1988) 444-450
45. Rickels K., Downing R., Schweizer E., and Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch. Gen. Psychiatry 50 (1993) 884-895
46. Rickels K., Schweizer E., DeMartinis N., Mandos L., and Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J. Clin. Psychopharmacol. 17 (1997) 272-277
47. Rickels K., DeMartinis N., Rynn M., and Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J. Clin. Psychopharmacol 19 Suppl. 2 (1999) 12S-16S
48. Rickels K., DeMartinis N., and Aufdembrinke B. A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 20 (2000) 12-18
49. Rickels K., DeMartinis N., Garcia-Espana F., Greenblatt D.J., Mandos L.A., and Rynn M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am. J. Psychiatry 157 (2000) 1973-1979
50. Rickels K., Pollack M.H., Sheehan D.V., and Haskins J.T. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. J. Psychiatry 157 (2000) 968-974
51. Rickels K., Zaninelli R., McCafferty J., Bellew K., Iyengar M., and Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry 160 (2003) 749-756
52. Rocca P., Fonzo V., Scotta M., Zanalda E., and Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr. Scand. 95 (1997) 444-450
53. Romach M., Busto U., Somer G., Kaplan H.L., and Sellers E. Clinical aspects of chronic use of alprazolam and lorazepam. Am. J. Psychiatry 152 (1995) 1161-1167
54. Salzman C., Miyawaki E.K., le Bars P., and Kerrihard T.N. Neurobiologic basis of anxiety and its treatment. Harv. Rev. Psychiatry 1 (1993) 197-206
55. Shader R.I., and Greenblatt D.J. Use of benzodiazepines in anxiety disorders. N. Engl. J. Med. 328 (1993) 1398-1405
56. Sir A., D'Souza R.F., Uguz S., George T., Vahip S., Hopwood M., Martin A.J., Lam W., and Burt T. Randomized trial of Sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J. Clin. Psychiatry 66 (2005) 1312-1320
57. Stocchi F., Nordera G., Jokinen R.H., Lepola U.M., Hewett K., Bryson H., and Iyengar M.K. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry 64 (2003) 250-258
58. Taylor D.P. Buspirone, a new approach to the treatment of anxiety. FASEB J. 2 (1988) 2445-2452
59. Taylor D.P. Serotonin agents in anxiety. Ann. N. Y. Acad. Sci. 600 (1990) 545-556
60. Taylor D.P., Carter R.B., Eison A.S., Mullins U.L., Smith H.L., Torrente J.R., Wright R.N., and Yocca F.D. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J. Clin. Psychiatry 56 Suppl. 6 (1995) 3-11
61. Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry 59 (1998) 502-508
62. Weiller E., Bisserbe J.C., Maier W., and Lecrubier Y. Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health Care. Br. J. Psychiatry (1998) 18-23
63. Wittchen H.U., Zhao S., Kessler R.C., and Eaton W.W. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 51 (1994) 355-364
64. Zohar J., and Westenberg H.G. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. Suppl. 403 (2000) 39-49